Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISEL: Gefitinib in Refractory Advanced NSCLC
NCT00242801Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 32
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2003; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00242801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242801.